This family of compounds represents a new class of drugs with lead candidates that are orally active, penetrate the BBB sufficiently to reach therapeutic concentrations, and reverse memory deficits seen in animal models of dementia
The study supplemented 12 marginally overweight older men with 1,000mg of Niagen daily for 21 days
The following dosing information is compiled from individual compound clinical trial data, peptide research community reports, and the pharmacological profiles of each compound
Alidoost et al
Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects
In another study, 11 patients suffering from senile dementia of the Alzheimers type were treated intravenously with ALC at 30 mg/kg for 10 days, and 1.5 g/day per os for 50 days, in three daily doses